Project Grant R41AI183969
Award Date
4/12/24
Completion Date
3/31/25
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Microbiotix, Inc. a $300,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to develop a novel therapy for treating Pseudomonas aeruginosa burn wound infections. The grant supports proof-of-concept experiments evaluating in vivo validated T3SS inhibitors, a class of small molecule compounds that inhibit the type 3 secretion system, a key virulence factor of Pseudomonas aeruginosa....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, to advance antimicrobial photodynamic therapy for preventing infection in osseointegrated prosthesis patients. The $426,648 award, with a period of performance from September 1, 2024 to July 31, 2026, will support research to improve treatments for...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 in funding to Ionic Pharmaceuticals, LLC to develop a quorum sensing inhibitor-based treatment for second-degree burn wound infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
The key products or services to be delivered through this award include: 1) Optimizing the formulation of a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Microrid Technologies Inc. located in Dix Hills, NY. The goal of this 1-year project is to discover and develop new antifungal therapeutics that target the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth and survival in host environments. The researchers will screen compound libraries to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of North Carolina at Chapel Hill (UNC-CH) to investigate the efficacy of combining the unsaturated fatty acid palmitoleic acid with the antibiotic vancomycin to treat complicated skin and skin structure infections (CSSIs). The project aims to determine how palmitoleic acid potentiates vancomycin's killing of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Rowan University a $474,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The research aims to improve the understanding of sequence-structure-activity relationships and leverage non-canonical amino acids to create novel peptides that mimic daptomycin's key mechanisms of calcium...
This $300,000 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is funding Biotherapeutics, Inc., a biotechnology company, to evaluate the comparative efficacy of their novel therapeutic candidate versus FDA-approved treatments for Clostridioides difficile infection (CDI) in mouse models. The key goals are to assess the impact on weight loss, disease activity, gut...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit limited liability company in Austin, Texas. The purpose of this 11-month grant is to develop a stable, aerosolizable dry powder formulation of bacteriophages (D29 phages) encapsulated in polymeric microparticles for the treatment of pulmonary tuberculosis (TB) infections. The key...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Trustees of the Colorado School of Mines. The award, totaling $384,554, aims to develop novel drug candidates that target the SUF-like pathway of iron-sulfur cluster biosynthesis as a treatment for drug-resistant infections caused by Gram-positive bacteria such as Staphylococcus aureus, Enterococcus faecalis, and...
This $778,534 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a "nanospray" treatment capable of penetrating and disrupting microbial biofilms in various types of wounds. The key objectives are to: 1) expand the library of cationic antimicrobials that can be effectively formulated with the polyelectrolyte surfactant nanoparticles, 2) evaluate the ability...